Valneva SE
NASDAQ:VALNBiotechnology
Healthcare
$5.37 +0.19%
+$0.01 today
- Market cap
- $510.36M
- Beta
- 1.40
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.80
52W Low $5.06High $12.25
Volume 0.00M
Average 0.09M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$52.89M
FY 2025 · Annual
Investing Cash Flow
-$1.71M
FY 2025 · Annual
Financing Cash Flow
-$621,000.00
FY 2025 · Annual
Cash Flow Statement
EUR
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73.43M) | (143.28M) | (101.43M) | (12.25M) | (115.19M) |
| Depreciation & Amortization | 14.28M | 21.04M | 17.58M | 19.59M | 21.75M |
| Deferred Income Tax | 3.45M | (1.54M) | 2.8M | 761K | 1.07M |
| Stock-Based Compensation | 14.51M | (8.66M) | 5.11M | 7.98M | 9.53M |
| Change in Working Capital | 36.13M | (145.98M) | (145.06M) | (11.57M) | (148K) |
| Accounts Receivables | (21.35M) | 12.4M | (2.86M) | 15.71M | 13.33M |
| Inventory | (92.37M) | 84.22M | (9.17M) | (6.8M) | 1.03M |
| Accounts Payables | 35.24M | (14.05M) | (17.4M) | 0 | 0 |
| Other Working Capital | 114.61M | (228.55M) | (115.65M) | (20.48M) | (14.51M) |
| Other Non-Cash Items | 81.96M | 33.07M | 18.25M | (71.72M) | 30.09M |
| Operating Cash Flow | 76.9M | (245.34M) | (202.74M) | (67.22M) | (52.89M) |
| Capital Expenditures | (93.17M) | (29.32M) | (14.31M) | (16.44M) | (4.48M) |
| Acquisitions (Net) | 0 | 8K | (10.95M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 841K |
| Other Investing Activities | 55K | 260K | 4.6M | 90.78M | 1.87M |
| Investing Cash Flow | (93.12M) | (29.05M) | (20.59M) | 76.92M | (1.71M) |
| Debt Repayment | (3.9M) | 34.49M | 75.89M | (6.49M) | 61K |
| Common Stock Issued | 166.82M | 189.84M | 0 | 0 | 30M |
| Common Stock Repurchased | 0 | 0 | (240K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (8.42M) | (9.21M) | (12.57M) | (19.97M) | (30.69M) |
| Financing Cash Flow | 154.5M | 215.12M | 63.08M | 30.68M | (621K) |
| Effect of Forex Changes | 3.96M | (828K) | (204K) | 1.81M | (3.4M) |
| Net Change in Cash | 142.29M | (57.21M) | (160.45M) | 42.19M | (58.62M) |
| Free Cash Flow | (16.27M) | (274.67M) | (217.06M) | (83.66M) | (57.38M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$115.2M
+ D&A$21.8M
+ Stock-Based Comp$9.5M
+ Deferred Tax$1.1M
- Working Capital-$148.0K
+ Other Non-Cash$30.1M
= Operating Cash Flow-$52.9M
- Capex-$4.5M
= Free Cash Flow-$57.4M
Analysis
FY2025 free cash flow is -$57.4M. FCF conversion is 49.8% of net income. Operating cash flow was -$52.9M, with capex of -$4.5M. The largest bridge item is Other Non-Cash at $30.1M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 13, 2026 | |
| 6-K | 6-K filing | Nov 6, 2026 | |
| 6-K | 6-K filing | Oct 15, 2026 | |
| 6-K | 6-K filing | Oct 8, 2026 | |
| 6-K | 6-K filing | Aug 14, 2026 |
Does VALN generate free cash flow?
Valneva SE (VALN) generated -$57.38M of free cash flow in fiscal 2025.
How much operating cash flow does VALN produce?
Operating cash flow was -$52.89M, before capital expenditures of $4.48M.
Continue the stock analysis
Jump to another research area for this company.